Compare SLMT & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLMT | ATOS |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7M | 25.9M |
| IPO Year | 2022 | 2010 |
| Metric | SLMT | ATOS |
|---|---|---|
| Price | $2.61 | $1.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 41.9K | ★ 54.3K |
| Earning Date | 12-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | $208.22 | N/A |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.53 |
| 52 Week High | $7.20 | $7.56 |
| Indicator | SLMT | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 31.30 |
| Support Level | $0.79 | N/A |
| Resistance Level | $3.36 | $2.60 |
| Average True Range (ATR) | 0.33 | 0.17 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 23.70 | 1.54 |
Solmate Infrastructure PLC is a Solana-based crypto infrastructure company with a strategic focus on Abu Dhabi. The group builds high-performance validators that lower latency, expand network reach, and position Abu Dhabi as a world-wide hub for Solana infrastructure. The company creates value by working with its partners to build infrastructure and real hardware for the crypto revolution. Its cutting-edge Solana staking infrastructure will help drive the adoption of the network in the Middle East.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.